1.50575

LiChrospher^® RP-select B (5 µm) HPLC Columns

L x I.D. 250 mm x 4.6 mm Hibar^® RT HPLC Column

• Synonym(e): TM=["LiChrospher"] C8 HPLC column
• UNSPSC-Code: 41115709
• NACRES: SB.52

Eigenschaften

• product name: LiChrospher^® RP-select B (5µm) Hibar^® RT 250-4.6, suitable for HPLC
• Materialien: stainless steel column
• Qualitätsniveau: 100
• Agentur: suitable for USP L7
• Produktlinie: LiChrospher^®
• Leistungsmerkmale: endcapped: no
• Kennzeichnungsgrad: 11.5% Carbon loading
• Parameter: 400 bar pressure; 60 °C max. temp.
• Methode(n): HPLC: suitable; mass spectrometry (MS): suitable (Low - Medium)
• Säule L × ID: 25 cm × 4.6 mm
• Oberflächenbereich: 350 m²/g
• Matrix: fully porous particle
• Aktive Matrixgruppe: C8 bonding phase
• Partikelgröße: 5 μm
• Porengröße: 60 Å pore size
• operating pH range: 2-7.5
• Trenntechnik: reversed phase; supercritical fluid (SFC)
• Lagertemp.: no temp limit

Beschreibung

Allgemeine Beschreibung

HPLC column

LiChrospher^® RP-select B is a versatile traditionally produced spherical silica gel carriers with reversed phase properties and with the hydrophobicity of a C-8 phase. This carrier is very well suited for the separation of basic compounds, but with still good properties for the determination of neutral and acidic compounds. This sorbent is packed into a Hibar 100-4.6 HPLC column. For mounting of a LiChroCART 4-4 guard column, the guard column holder 1.51487 has to be used.

Anwendung

• Simultaneous quantification of delta-9-THC, THC-acid A, CBN and CBD in seized drugs using HPLC-DAD: This study utilizes high-performance liquid chromatography with diode-array detection (HPLC-DAD), employing a LiChrospher^® RP-select B column to effectively separate and quantify cannabinoids in forensic samples, highlighting its application in legal and forensic settings (Ambach et al., 2014).


• Structural characterization of stress degradation products of Darunavir: Employing LC-MS/MS alongside HPLC, this research underscores the utility of the LiChrospher^® RP-select B column in the stability analysis of HIV medications, crucial for ensuring drug safety and efficacy (Rao et al., 2014).


• RP-HPLC separation and characterization of unknown impurities of Darunavir: This study demonstrates the column′s role in identifying and quantifying impurities in HIV-protease inhibitors, contributing to the pharmaceutical industry′s quality control measures (Nageswara Rao et al., 2013).


• Quantification of pralidoxime in urine by ion pair chromatography: The LiChrospher^® RP-select B column is applied in a biomedical context to monitor therapeutic agents in clinical settings, supporting patient treatment regimes (John et al., 2012).


• Liquid chromatography/electrospray tandem mass spectrometry method for determination of cefuroxime: This analytical method facilitates the study of pharmacokinetics in clinical pharmacology, using the LiChrospher^® RP-select B column for precise drug monitoring in plasma (Partani et al., 2010).

Hinweis zur Analyse

Druck: ≤ 90 bar
Theoretische Bodenzahl (N/m) (Toluol): ≥ 50000
Symmetrie (Toluol): 0.8 - 1.4
Kapazitätsfaktor (Toluol): 1.0 - 2.0

Rechtliche Hinweise

Hibar is a registered trademark of Merck KGaA, Darmstadt, Germany

LiChrospher is a registered trademark of Merck KGaA, Darmstadt, Germany